Ocugen's Cash Runway Through 2028 and New CMO Set Stage for Pivotal Q3 Data
13.06.2026 - 18:13:15 | boerse-global.de
Ocugen has stocked its war chest and locked in management changes, even as the stock wallows 55% below its March peak. Shareholders approved board elections and a say-on-pay frequency at the June 11 virtual meeting, while the company appointed Mohamed Genead as permanent Chief Medical Officer — moving him from the interim role he had held. The approvals came on a routine slate: 139.6 million shares were represented, Kirsten Castillo and Satish Chandran were elected Class III directors until the 2029 annual meeting, and PricewaterhouseCoopers was confirmed as auditor for fiscal 2026.
The real drama awaits in the third quarter. Three clinical milestones are clustered together, the most critical being the planned rolling submission of a biologics license application for OCU400, the company's lead mutation-agnostic gene therapy for inherited retinal disease. The Phase 3 trial has fully enrolled all 140 patients, with final data expected early 2027. Alongside that filing, Ocugen expects interim data from the OCU410ST study in geographic atrophy, and the Phase 3 trial for that same indication is set to launch this summer, following positive 12-month Phase 2 results.
The company's cash position supports that workload. In May, Ocugen raised $130 million through convertible notes due 2034 carrying a 6.75% coupon. Proceeds were partly used to retire roughly $33 million in debt owed to Avenue Capital Group, extending the cash runway to 2028. That financial breathing room contrasts sharply with the stock's recent slide: at €1.05, Ocugen has lost 11% year to date and more than 16% in the past 30 days alone.
Should investors sell immediately? Or is it worth buying Ocugen?
Technically, the shares sit below both the 50-day and 200-day moving averages of €1.32. The relative strength index of 34.5 hovers just above the oversold threshold of 30, while annualized 30-day volatility clocks in at 67% — a typical reading for a late-stage biotech with binary catalysts. The 52-week range spans from €0.78 to €2.35, leaving ample room for a swing in either direction.
The near-term calendar offers potential sparks. CEO Shankar Musunuri is presenting the company's modifier gene therapy platform this week at Clinical Trials at the Summit in Las Vegas, followed by a slot at the BIO International Convention in San Diego at the end of June. These appearances give management the chance to frame the Q3 narrative before the OCU400 filing and interim readout take center stage.
If the rolling BLA is submitted on schedule and the OCU410ST interim data hold up, a first U.S. approval could come as early as late 2027. For now, Ocugen's pipeline momentum and extended cash runway stand in stark contrast to the market's punishing view of its stock.
Ad
Ocugen Stock: New Analysis - 13 June
Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
